Skip to main content

Erythroplakia clinical trials at UCSD

2 in progress, 0 open to eligible people

Showing trials for
  • Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

    Sorry, not yet accepting patients

    This phase II trial tests whether metformin works in preventing oral cancer in patients with oral leukoplakia (white patches) or erythroplakia (red patches). Metformin is in a class of drugs called biguanides. Metformin helps to control the amount of glucose (sugar) in the blood. It decreases the amount of glucose patients absorb from food and the amount of glucose made by the liver. Metformin also increases the body's response to insulin, a natural substance that controls the amount of glucose in the blood. This trial may help researchers determine if metformin can stop changes in the mouth that are related to pre-cancer growths in the mouth.

    San Diego, California and other locations

  • Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

    Sorry, in progress, not accepting new patients

    This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.

    San Diego, California and other locations

Our lead scientists for Erythroplakia research studies include .

Last updated: